Osteotech’s MagniFuse
This article was originally published in The Gray Sheet
Executive Summary
Bone graft material will launch in mid-2009 into the estimated $1.2 billion U.S. market for bone graft substitutes, Osteotech says Nov. 7. The device recently received 510(k) clearance as a bone graft substitute and bone void filler for use in the spine, pelvis and extremities. The product combines allograft bone within a polymer mesh that provides targeted and contained delivery, and avoids issues with graft site migration or irrigation often seen with other bone graft substitutes, Osteotech says. The device allows Osteotech to go head-to-head with bone morphogenetic protein products, says Osteotech President-Domestic Robert Wynalek
You may also be interested in...
Medtronic Expands Ortho Biologics Presence With Osteotech Acquisition
Medtronic is shoring up its orthopedic biologics business through the acquisition of demineralized bone matrix marketer Osteotech for $123 million, announced Aug. 17
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.